The benefits of clopidogrel on the treatment of acute coronary syndromes are well established. However, not all patients respond in the same way to clopidogrel therapy, and there are patients who suffer major adverse cardiovascular events despite being on treatment, emerging the concept of clopidogrel resistance. This book focuses on this topic, mainly in the definition, response assessment, clinical implications, patients’ management and emerging therapies (prasugrel, cangrelor and ticagrelor). (Imprint: Nova Biomedical)
We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.